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The treatment of cystinuria is hampered by methods used to
measure urinary lithogenicity. Most cystine assays cannot
reliably distinguish cystine from soluble thiol drug–cysteine
complexes. We used a solid-phase assay of urinary cystine
capacity in a large sample of patients with cystinuria. A
known amount of solid-phase cystine is added to urine.
In supersaturated urine, cystine precipitates onto added
crystals, so the solid phase recovered after incubation will
be greater than that added. We studied the effect of
cystine-binding thiol drugs (CBTD) to solubilize cystine and
determined correlates of cystine capacity in patients who
were and were not taking CBTD. Increasing concentrations of
D-penicillamine, tiopronin and captopril dissolved cystine in
urine with similar efficacy. A general linear model in which
24 h cystine excretion was the dependent variable showed
that creatinine, urea nitrogen, and sodium excretions were
associated with cystine excretion (Po0.02, all three). Urine
volume, pH, and cystine excretion strongly correlated with
cystine capacity (Po0.001). Tiopronin had no effect on
supersaturation in a cross-sectional analysis. A subset of
supersaturated samples, with negative cystine capacity,
occurred mainly among women not taking CBTD. For
this subset, capacity differed significantly between CBTD
users and non-users; use of CBTD avoided extremes of
supersaturation. Female enrichment in the supersaturated
group was accounted for in part by underprescription of
CBTD to women. This assay of cystine capacity was reliable
in the presence of CBTD. It should be useful in monitoring
patients’ response to dietary interventions and
administration of fluid, citrate, and CBTD.
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The treatment of cystinuria is currently hampered by the
available methods used to measure the lithogenicity of urine
from patients with cystinuria. One problem is that measure-
ment of cystine excretion is complicated by artifactually low
values when cystine solubility is poor. Cystine is least soluble at
pH 5–7, a range frequently found in human urine. Adding acid
to 24 h urine collections was used in the past to assure that all
excreted cystine remained in solution. However, acidification
during collection prevents measurement of urine pH, a critical
factor in determining cystine solubility. This problem can be
surmounted by alkalinization of the sample after the urine
collection is completed and pH measured.1
Another problem is that many cystine assays do not
reliably distinguish cystine from soluble thiol drug–cysteine
complexes. Colorimetric reactions measure the amount of
free sulfhydryl group. In the presence of thiol-containing
drugs, this no longer remains an accurate estimate of cystine
concentration; the drugs themselves may be detected by the
colorimetric assay. High-performance liquid chromatography
and other chromatographic techniques can distinguish thiol
drug from cystine and cysteine but often the sample
preparation leads to disruption of thiol drug–cysteine
complex.2,3 The result is that clinicians cannot estimate the
extent to which the thiol drug has reduced the relevant
cystine saturation. Even in patients not treated with thiols,
supersaturation cannot be accurately predicted from mea-
surement of pH and cystine concentration, as the effect of pH
on cystine solubility varies among patients.4,5 Finally, no
studies demonstrate correlation of rates of cystine stone
formation or growth with any measure of urine cystine
excretion or concentration.
We sought to overcome these problems with an assay of
cystine supersaturation (CSS). Such an assay would directly
measure the ability of an individual patient’s urine to
solubilize or precipitate cystine, called cystine capacity.
Measurements of total cystine are not critical, and the
solubilizing effects of cystine-binding thiol drugs (CBTD) can
be accurately measured. Previously, the efficacy of CBTD
could be measured only with the passage of time and
estimates of stone growth or dissolution. We report our
initial measurements of cystine capacity in patients with
cystinuria and the effect of CBTD on urinary cystine capacity.
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RESULTS
Performance of solid-phase assay in urine
We demonstrated the reliability of the solid-phase assay by
studying its ability to account for all dissolved cystine from
urine (Figure 1). Cystine crystals were added to urine of
patients with cystinuria taking CBTD (n¼ 10) and not taking
CBTD (n¼ 12), and stirred for 48 h at 371C. When greater
amounts of cystine were added to urine, dissolved cystine in
the supernatant reached a plateau at 1.4 mM. As more solid-
phase cystine was added and not dissolved, the amount of
cystine remaining in the solid-phase rose proportionately.
The sum of the supernatant and solid phases at each point
rose appropriately, indicating that cystine recovery was
complete and reliable.
Effects of CBTD on cystine capacity
Figure 2 shows the ability of increasing concentrations of
D-penicillamine, tiopronin, and captopril to dissolve solid-
phase cystine in urine. The slopes of all three lines are similar,
indicating that all three have similar efficacy in causing
dissolution of preformed cystine crystals. From the slope, we
estimate that CBTD are able to bind cysteine (each cystine
yields two cysteine) at a molar drug:cysteine ratio of 1.25–1.0
in these in vitro conditions. In clinical use, captopril levels in
urine do not approach those of tiopronin and penicillamine,
limiting its efficacy.
Determinants of cystine excretion
For this analysis, urine samples from subjects taking
captopril or D-penicillamine were excluded, as these CBTD
affect cystine measurement in the cystine assay used;
tiopronin does not. Thus, 79 urine samples are included in
this analysis. Using a general linear model in which 24 h
urine cystine excretion was the dependent variable and all
standard urine chemistries, gender, and tiopronin use were
included, 24 h urine creatinine, urea nitrogen, and sodium
excretions were independently associated with cystine
excretion (Po0.02 for all three; r2 for the complete model
was 0.56). There was a modest effect of gender (adjusted
least square excretions were 3.3 vs 3.8 mmol/day, male vs
female, P¼ 0.038). Use of tiopronin was without significant
effect (P¼ 0.06). The correlation of urine cystine excretion
with urine creatinine (Figure 3, upper right panel) was
strong, although there was a significant difference between
men and women (r2¼ 0.36, Po0.001 for men; r2¼ 0.52,
Po0.001 for women). The cystine excretion was lower
for a given creatinine among men than women. Urine
cystine excretion was correlated with urine sodium
excretion (r2¼ 0.38, Po0.001; Figure 3, upper left panel)
and urine cystine per gram creatinine was correlated with
urine sodium per gram creatinine (Figure 3, upper middle
panel; gender had significant effect, Po0.01; r2¼ 0.15,
Po0.01 for men, r2¼ 0.27, Po0.001 for women). The
correlation of urine urea nitrogen and cystine excretion was
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Figure 1 | Performance of solid-phase assay. Cystine crystals were
added to urine from patients taking CBTD (n¼ 10) and not taking
CBTD (n¼ 12) and stirred for 48 h at 371C. As the result did not vary
whether patients were taking or not taking CBTD, the two groups
were combined. Filled circles indicate that when greater amounts of
cystine were added to urine, dissolved cystine in the supernatant
reached a plateau at 1.4 mM, the point of saturation. (Error bars¼72
s.e.m.). Open circles indicate that the amount of cystine remaining in
the solid phase (precipitate, PPT) rose proportionately as cystine
dissolution plateaued at saturation. Triangles represent the sum of
the supernatant and solid phases and indicate that cystine recovery
was complete and reliable.
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Figure 2 | Effects of CBTD on cystine capacity. Increasing concentrations of CBTD (D-penicillamine, tiopronin, and captopril) in urine dissolved
more solid-phase cystine, shown on y axis. The slopes of all three lines are similar. The dotted lines represent the maximum amount of cystine
added to each sample. Less cystine was added to study the effect of captopril than for D-penicillamine and tiopronin because captopril achieves
lower urinary concentrations than the other two.
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also strong (Figure 3, lower left panel; r2¼ 0.49, Po0.001;
gender was not significant). When urine urea nitrogen was
factored for urine creatinine, the correlation persisted
although gender differences were significant (Figure 3, lower
middle panel, gender effect Po0.01; r2¼ 0.30, Po0.001 for
men, r2¼ 0.25, P¼ 0.001 for women). Finally, a multivariable
score created using pH, urine urea nitrogen, and creatinine
correlated very strongly with cystine excretion (Figure 3,
lower right panel, r2¼ 0.54, Po0.001). Calcium, citrate, and
uric acid excretion were not independently associated with
cystine excretion.
Cystine solubility
We used a general linear model in which 24 h urine cystine
solubility was the dependent variable and all standard urine
chemistries, initial cystine concentration, and use of tiopro-
nin were included. The solubility of cystine as determined by
the concentration of cystine in urine after incubation with an
excess of solid phase was correlated with both urine pH and
initial cystine concentration of the urine (Figure 4, upper
panels; r2¼ 0.14, P¼ 0.002 for urine pH and r2¼ 0.18,
Po0.001 for initial cystine concentration). As cystine
concentration is the result of 24 h cystine excretion and
urine volume, both variables were tested: the urine cystine
excretion had a modest correlation with solubility (r2¼ 0.06,
P¼ 0.03) whereas the urine volume did not correlate
significantly with solubility (r2¼ 0.03, P¼ 0.1). Use of
tiopronin did not have a significant interaction in the general
linear model and gender did not have an influence on cystine
solubility.
Cystine saturation
We used cystine uptake from an excess of solid phase (cystine
capacity) to gauge urine saturation. Negative values for
cystine capacity represent urine supersaturated with cystine;
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Figure 3 | Variables associated with cystine excretion. Increasing 24 h urine urea nitrogen (UUN), sodium and creatinine excretions were
independently and strongly associated with increasing cystine excretion (Po0.01 for all). Circles: males; triangles: females; open symbols: no
CBTD; closed symbols: CBTD. Ellipses enclose 1 standard deviation from the mean; solid line: males; broken line: females.
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Figure 4 | Variables associated with cystine solubility. Cystine
solubility was strongly correlated with both urine pH and initial
cystine concentration of the urine. CBTD had no effect on cystine
solubility. Circles: males; triangles: females; open symbols: no CBTD;
closed symbols: CBTD. Ellipses enclose 1 standard deviation from the
mean; solid line: males; broken line: females.
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positive values represent undersaturation. In a general linear
model, we used solid-phase uptake as the dependent variable
and included all standard urine chemistries, initial cystine
concentration and use of CBTD and alkali. Urine samples
collected from patients taking captopril and/or D-penicilla-
mine are included, as the measurement of cystine capacity is
not affected by these medications. Like solubility, saturation
was controlled mainly by the initial urine cystine concentra-
tion and by urine pH (Figure 5, left hand panels, top and
bottom; r2¼ 0.48 for cystine concentration and r2¼ 0.19 for
urine pH, Po0.001 for both). The effect of cystine
concentration on cystine capacity was more striking for
men than women, as evidenced by the more narrow ellipse of
containment (Figure 5, top left panel). Of interest, virtually
all urine samples with an initial cystine concentration
below 1 mM were undersaturated. As cystine concentration
is the result of 24 h cystine excretion and urine volume,
we tested both variables (Figure 5, upper middle and
right panels): both variables significantly correlated with
cystine capacity (r2¼ 0.07, P¼ 0.02 for cystine excretion,
r2¼ 0.24, Po0.001 for urine volume). A score using
urine volume, cystine excretion, and urine pH strongly
correlated with cystine capacity, (Figure 5, lower middle
panel, r2¼ 0.5, Po0.001) and cystine solubility accounted for
only a small amount of variation in solubility (P¼ 0.01,
r2¼ 0.09).
Effect of CBTD on cystine capacity
Use of tiopronin did not have a significant interaction in the
general linear model for determinants of cystine solubility
(Figure 4). Tiopronin also had no apparent effect on mean
values for CSS, and was clearly of little consequence in either
gender (Figure 5). Mean values of cystine capacity were
0.2970.1 mM in CBTD users and 0.1170.1 mM in non-users
(P¼ nonsignificant (NS)). Although means for CBTD users
did not differ from those of non-CBTD users, a group of
supersaturated urine samples, with negative cystine capacity,
mainly among women not taking CBTD, can be seen in
Figure 5 (upper left panel, open symbols). For this subset of
29 urine samples, values for cystine capacity differed
significantly between CBTD users and non-users (0.56 vs
0.27 mM uptake, no CBTD vs CBTD, P¼ 0.019). There were
more women than men among patients with supersaturated
urine. We attribute this female preponderance to a general
underprescription of CBTD to women (24 of 37 men vs 12 of
32 women were given CBTD, w2¼ 5.15, P¼ 0.023). This
disparity in prescribing patterns differs markedly from the
more uniform prescription of alkali (23 of 37 men vs 23 of 32
women were given alkali, w2¼ 0.73, P¼NS).
DISCUSSION
The management of cystinuria consists of increasing fluid
intake, alkalinizing urine, and using CBTD. Judging the
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Figure 5 | Effect of CBTD on cystine capacity. Cystine capacity was strongly correlated with the initial cystine concentration of the urine and
with urine pH (Po0.001 for both). Increasing cystine concentration was associated with more negative cystine capacity, in both CBTD users and
non-users. The more supersaturated women not taking CBTD are seen as the tail of open triangles outside the ellipses. Daily cystine excretion
was not correlated and urine volume and cystine solubility were modestly correlated with cystine capacity (Po0.05). A model incorporating
urine volume, cystine excretion and urine pH shows an excellent correlation with cystine capacity (Po0.001). Circles: males; triangles: females;
open symbols: no CBTD; closed symbols: CBTD. Ellipses enclose 1 standard deviation from the mean; solid line: males; broken line: females.
Dashed horizontal line represents cystine saturation, with values above the line representing undersaturated urine and values below the line
representing supersaturated urine.
1044 Kidney International (2006) 69, 1041–1047
o r i g i n a l a r t i c l e DS Goldfarb et al.: Cystine excretion and capacity in cystinuria
success of medical therapy based on changes in urinary
variables such as cystine excretion and pH has not been
entirely satisfactory however.6 Because of substantial inter-
patient variability, cystine solubility in individual urine
samples is not reliably calculated from nomograms employ-
ing cystine concentration and urinary pH data alone.4,5
Further complicating management, measurements of cystine
excretion cannot be interpreted in a straightforward manner.
First, cystine excretion and supersaturation may be under-
estimated in samples due to cystine precipitation.5 Second,
measurement of cystine is complicated by the presence of
CBTD. Many cystine assays use preparation steps that break
thiol–cysteine bonds, leading to release of free cysteine, which
recombines with itself to form the insoluble dimer cystine.
CBTD themselves, active because they contain the active thiol
group similar to that of cysteine, variably interfere with the
measurement of cystine as well, so that the drugs and amino
acids are not entirely or reliably distinguished.1 The result is a
lack of useful values to correctly titrate CBTD doses,
minimize their frequent drug-induced side effects, and judge
success of therapy. Lacking a reliable predictor of response to
therapy, only the passage of time with serial assessment of
stone formation can realistically assess adequacy of treat-
ment.
Our solid-phase assay of urinary cystine, which leads to
direct measures of urinary CSS and cystine capacity, is
reliable in the presence of CBTD.1 We demonstrated its utility
in directly measuring supersaturation in urine of patients
with cystinuria.5 The current report applies this assay to a
large cohort of patients including those taking and not taking
CBTD. The solid-phase assay was successful in accounting for
added cystine whether in the presence or absence of CBTD
(Figure 1). The assay also demonstrated that increasing
concentrations of D-penicillamine, tiopronin, and captopril
caused expected increases in in vitro cystine capacity. Given
these operating characteristics, we believe that the assay will
be of clinical utility in measuring urinary cystine capacity in
patients taking CBTD. The assay could help find an optimally
efficacious dose of CBTD. A satisfactory increase in cystine
capacity could allow physicians to prescribe a minimal dose
and limit side effects of the medications.
The ability of restriction of dietary animal protein and salt
intake to lower urinary cystine excretion and diminish stone-
forming activity has been debated. Our data demonstrate
strong relationships of urinary sodium and urea excretion to
cystine excretion (Figure 3). That salt restriction reduces
cystine excretion has been demonstrated in relatively small
studies in both adults and children.7,8 These studies reported
acute effects (after several weeks) of changes in sodium intake
to alter cystine excretion. Our data confirm this finding in a
larger sample and in a cross-sectional analysis. How salt
excretion affects cystine excretion is not known. Both sodium
chloride and sodium bicarbonate administration cause
increased urinary cystine excretion.9 The cystine transport
process affected by the disease-causing mutations in SLC3A1
(rBAT) and SLC7A9 (b0,þAT) is sodium-independent.10 The
effect of increasing sodium intake to increase cystine
excretion could occur due to an unexplained influence of
sodium transport on cystine transport in the proximal tubule
or via more indirect effects of sodium intake on angiotensin
II or aldosterone metabolism if levels of these substances are
relevant to renal cystine handling. Also not known is whether
increases or decreases in salt intake mediate changes in net
cystine balance or cystine metabolism. In vitro studies suggest
that the deleterious effect of increasing sodium intake to
increase cystine excretion could be offset by a favorable effect
of ionic concentration on cystine solubility in urine.4
However, in our data, sodium excretion was not an
independent variable determining cystine solubility in either
direction. No prospective studies have demonstrated changes
in stone activity as the result of sodium-restricted diets.
Protein restriction has been prescribed for patients with
cystinuria based on the premise that reduced ingestion of
methionine, cystine’s dietary precursor (and cystine itself),
will lower cystine excretion. One study demonstrated that
diminished intake of cystine’s dietary precursor methionine
reduces urinary cystine excretion.11 However, the ability of
such diets to cause clinically meaningful effects and of
patients to adhere to such regimens has been questioned. We
show a tangible relationship between increased urinary urea
excretion, a marker of protein ingestion, and cystine
excretion (Figure 3). Creatinine excretion also correlated
with cystine excretion. This could result from people with
larger muscle mass ingesting more methionine-containing
animal protein and excreting more cystine. Alternatively, it
implies that a significant proportion of urinary cystine
derives from endogenous muscle turnover.
We cannot explain the correlation between cystine
solubility and cystine concentration of urine. As the range
of cystine solubility in human urine is large and cannot be
fully accounted for by urine pH, there must be other factors
that control solubility. Further work is needed to identify
them. As expected, cystine capacity independently correlated
with cystine concentration of urine as well as its pH. In
contrast, an unanticipated finding was the lack of an
independent effect of CBTD on values of cystine capacity
for the entire study population. Many papers have reported
successful treatment of cystinuria with CBTD, both tiopro-
nin12,13 and D-penicillamine,14 and one would expect that
this success would require a reduction in CSS. Most of the
patients studied here were taking tiopronin and lack studies
off and on CBTD; we cannot be certain if the drugs effectively
lowered CSS levels in most patients. The mean values of
cystine capacity for patients taking and not taking CBTD
were indistinguishable. However, extremes of supersaturation
occurred almost exclusively in patients not taking CBTD
(Figure 5, left panel). The most negative cystine capacity
values occurred in seven women and one man not taking
CBTD and one man taking CBTD, constituting the best
evidence in this study for a benefit of CBTD. Whether the
higher proportion of women in this subgroup with high
supersaturation values occurred because women were less
Kidney International (2006) 69, 1041–1047 1045
DS Goldfarb et al.: Cystine excretion and capacity in cystinuria o r i g i n a l a r t i c l e
willing to take CBTD, or because physicians prescribed the
drugs less frequently to women cannot be determined. We
previously demonstrated the beneficial effect of CBTD on
urinary cystine capacity in seven patients who did 24 h urine
collections while on and off CBTD.15 Six of seven patients
had an increase in cystine capacity on CBTD compared to off
drug.
A limitation of our data is that we do not know the dose
of CBTD patients were taking. The lack of an effect on mean
values of saturation could result from inadequate doses or
poor compliance. On the other hand, as the physicians
referring the patients were urologists and nephrologists
(including ourselves) with active stone clinics and relatively
sizeable populations of patients with cystinuria, we suspect
that CBTD were prescribed in appropriate dosages. Our
observations regarding the effects of CBTD are also
influenced by the possibility that the patients who are
prescribed CBTD are the most active stone-forming patients
and have higher initial supersaturations than those not
prescribed drugs, and once treated have cystine capacity
values similar to those not treated with CBTD.
It may be that not all patients achieve benefit in reducing
cystine capacity or supersaturation from CBTD although the
reasons for such differences are currently not known. In our
previous study of cystine capacity on and off CBTD, patients
with the most saturated urine (negative capacity values) had
greater effects than patients with relatively less saturated
urine (more positive capacity).15 That study’s paired design
has greater efficacy in demonstrating the potential benefit of
CBTD as compared to the current cross-sectional compar-
ison. Our assay may therefore be put to best use in
determining responses of individual patients to therapeutic
maneuvers such as prescription of citrate, CBTD and fluid
and dietary manipulations.
The stone-preventing efficacy of CBTD has not been
demonstrated in a randomized controlled trial, although
uncontrolled reports of efficacy have been published since the
1960s for D-penicillamine and since the 1980s for tiopronin.
The relative advantage of CBTD as compared with urinary
alkalinization and/or fluid intake has not been directly
established. Only anecdotal reports using small numbers of
historical controls have demonstrated the drugs’ impact.14
There is certainly a need for controlled clinical trials of
available medical therapies. The relative roles of the various
determinants of cystine capacity need to be explored in such
studies, so that measurements of urinary cystine capacity
could be correlated with clinical benefit. It would then be
possible to select patients with greater predicted responses
from CBTD and for the response to therapy to be gauged in a
more reproducible method than what is currently available.
MATERIALS AND METHODS
We measured urinary cystine using a nitroprusside colorimetric
assay and cystine solubility and capacity using a solid-phase assay.
Cystine excretion is the amount of cystine excreted in a timed
collection, expressed as millimoles per day or as millimoles per gram
of urinary creatinine. Urine was incubated with cystine crystals, the
‘solid phase’, for 48 h. Cystine solubility is the final concentration of
dissolved cystine at the end of the incubation period, when cystine
in the solid phase and in urine are at equilibrium, in millimoles per
liter. At equilibrium, urine is saturated with cystine: higher
concentrations represent supersaturation, lower concentrations,
undersaturation. Cystine capacity is measured using 25 ml samples
and expressed as the change in size of the solid phase, in millimoles.
The uptake of solid-phase cystine by urine occurs in the case of
undersaturated urine and is expressed as positive cystine capacity;
the giving up of cystine to solid phase occurs in the case of
supersaturated urine and is expressed as negative cystine capacity.
Cystine assay
The assay was identical to that reported previously.1,5,16 A 100ml
portion of urine was diluted with 400ml H2O and 1 ml phosphate-
buffered saline buffer, pH 7.4 (Sigma-Aldrich Co., St Louis, MO,
USA). A 300 ml portion of a 10% sodium cyanide solution was
added and the mixture incubated at room temperature for 20 min.
Addition of 100ml of a 20% sodium nitroprusside solution initiates
a colorimetric reaction linearly related to the concentration of
cystine present. Absorbance was measured within 20 s of the
nitroprusside addition at 521 nm using a Beckman DU 650
spectrophotometer and concentration calculated from a standard
curve run with each assay. The intra-assay coefficient of variation is
2.9% and the inter-assay coefficient of variation 2.6% in this
laboratory.
Cystine capacity assay
To 25 ml of urine, maintained at original pH, a known amount of
solid-phase cystine (Sigma-Aldrich Co.) was added and incubated
for 48 h at 371C with constant stirring. Solid phase was harvested by
centrifugation at 3800 r.p.m. for 20 min at room temperature. The
supernatant was removed and the remaining pellet dissolved in
25 ml of high-pH buffer (0.1 M sodium carbonate, pH 9.9). Cystine
concentration was determined in the supernatant and high-pH
buffer as described above. The sum of cystine in the supernatant and
in the residual solid phase should equal the sum of the amount of
cystine added and the amount of cystine in the original urine. The
assay was performed using urine from patients who were and were
not using CBTD. Undersaturated urine will dissolve some solid-
phase cystine, so the amount of solid-phase cystine recovered after
48 h of incubation will be lower than that originally added. In
supersaturated urine, cystine precipitates from solution onto added
cystine crystals; the amount of solid phase recovered after
incubation will be greater than that originally added.
Effects of CBTD on cystine capacity
To determine the effects of CBTD on the cystine capacity assay, we
added increasing amounts of D-penicillamine, tiopronin or captopril
to 25 ml of urine. Four patients with cystinuria not taking CBTD
participated, and the mean of the results of four experiments was
taken. A fixed amount of cystine was added: for tiopronin and
D-penicillamine, 40 mg, to achieve a concentration of 6.67 mM; for
captopril, 20 mg, to achieve a concentration of 3.33 mM. The lower
amount of solid-phase cystine in the captopril assay reflects the
lower urine concentration attainable clinically with this drug.
Tiopronin and D-penicillamine are usually prescribed in doses of
5–15 mmol/day compared to captopril at 0.5–1 mmol/day. Incuba-
tion was carried out as in the preceding section. After 48 h, pellet
and supernatant were separated and the pellet processed in high-pH
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buffer as above. Cystine concentration was determined in the
recipient high-pH buffer to calculate the amount of cystine
dissolved in urine.
Characterization of urine of patients with cystinuria
We analyzed a total of 91 24 h urine collections from 69 stone-
forming patients (37 male and 32 female patients) with cystinuria
(defined as excretion greater than 250 mg of cystine per 24 h).
Patients were taking medications and following diets as prescribed
by their physician. Forty-four urine samples were collected while
patients were taking tiopronin, four of whom were also taking
captopril. Four urine samples were collected while patients were
taking D-penicillamine and four were collected while patients were
taking only captopril. Thirty-three urine samples were collected
from patients not receiving alkali therapy and 58 urine samples were
collected while patients were taking alkali. Of the latter, 35 were
taking concomitant CBTD. Sixteen samples were collected from
patients taking neither CBTD nor alkali. Seven of the 69 patients
were children and they contributed 10 urine collections.
Urine was collected from patients for 24 h at home. Urine
samples were not refrigerated. An antibacterial preservative and a
volume marker were added to the collection container at the
beginning of the collection. Patients removed a 50 ml aliquot and
alkalinized the rest of the collection with Na2CO3 to bring any
precipitated cystine into solution.5 They removed a 50 ml aliquot
from the alkalinized collection, and sent the aliquots of the original
urine and the alkalinized sample to the laboratory by overnight
delivery. Cystine concentration was measured on both samples. The
higher value was used to calculate CSS. CSS is the total
concentration of cystine in urine divided by the concentration of
cystine at saturation after incubation with solid-phase cystine.
Cystine capacity is defined as the change in the amount of cystine
dissolved after addition of solid-phase cystine to an alkalinized
sample in mmol/l: a positive number indicates an undersaturated
sample that took up cystine from solid phase; a negative number
indicates a supersaturated solution that precipitates cystine onto
solid phase.
Urine samples were also analyzed by standard analytic techniques
for concentration of sodium, potassium, citrate, chloride, urea
nitrogen, creatinine, pH, calcium, oxalate and phosphate.17 Clinical
data included total number of stones, stones formed in the last 2
years and drugs taken at the time of the urine collections, including
CBTD and citrate supplementation. Data regarding stone activity
were not of sufficient quality to permit an analysis correlating them
with urinary cystine measurements. Data for body weight were not
available.
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